Can a single injection reprogram immune cells to fight cancer?
NCT ID NCT07774572
First seen Aug 19, 2026 · Last updated Aug 19, 2026
Summary
This early-stage trial is testing an experimental therapy that uses circular RNA to create CAR T cells directly inside the body, potentially eliminating the need to extract and modify cells in a lab. It is designed for adults with relapsed or refractory B-cell cancers, such as certain lymphomas and leukemias, who have not responded to standard treatments. The study will evaluate the therapy's safety, tolerability, and preliminary effectiveness, with a focus on finding the right dose and observing how the body responds.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- In vivo circular RNA chimeric antigen receptor (CAR) T cell therapy
- What this could lead to
- If successful, this approach could offer a one-time treatment that reprograms a patient's own immune cells to attack and potentially eliminate B-cell cancers, without the need for complex lab processing.
- What could go wrong
- This is an early-phase, dose-escalation trial with a small number of participants, so safety and effectiveness are not yet established. There are risks of severe side effects, and the therapy may not work for all types of B-cell malignancies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ruijin Hospital
NOT_YET_RECRUITINGShanghai, China
-
The Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immune cell therapy outsmart resistant blood cancers?
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Engineered immune cells take aim at Hard-to-Treat lymphomas